Back to Feed
ClinicalTrials.gov|Clinical Trial
ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients
University of Florida
Abstract
This study will enroll 6 DLT evaluable subjects (up to 12 patients total) where we will evaluate feasibility and safety of adoptive cellular therapy combined with IDH1/2 inhibitors in patients with recurrent or progressive oligodendroglioma WHO grade 2 and WHO grade 3. Phase: PHASE1 Status: ACTIVE_NOT_RECRUITING Conditions: Recurrent Oligodendroglioma; Progressive Oligodendroglioma Interventions: TTRNA-DC vaccines with GM-CSF; Autologous Hematopoietic Stem cells (HSCs); TTRNA-xALT; Td vaccine
Keywords
Recurrent OligodendrogliomaProgressive Oligodendroglioma